Table 3 The ongoing clinical trials of microbiota-associated metastatic colorectal cancer
From: Role of imbalanced gut microbiota in promoting CRC metastasis: from theory to clinical application
NCT number | Status | Interventions | Phases | Purposes |
|---|---|---|---|---|
NCT04729322 | not recruiting | procedure: biopsy, FMT; drugs: FMT capsule, metronidazole, neomycin, vancomycin; biological: nivolumab, pembrolizumab; Other: questionnaire | Phase 2 | adjuvant treatment: evaluate the efficacy of pembrolizumab or nivolumab in conjunction with FMT |
NCT03941080 | recruiting | diagnostic test: fecal sample, blood sample; behavioral: questionnaire | not applicable | adjuvant treatment: study the relation between the gut microbiome and the effects of chemotherapy |
NCT04131803 | not yet recruiting | drugs: Bifico (also known as “bifidobacterium trifidum live powder”, a probiotic preparation) combined with chemotherapy plus targeted therapy, chemotherapy plus targeted therapy | not applicable | adjuvant treatment: assess Bifico combined with standard chemotherapy plus targeted therapy compared to standard chemotherapy plus targeted therapy for efficacy and safety of metastatic colorectal cancer |
NCT06049901 | recruiting | drug: nitazoxanide | Phase 3 | adjuvant treatment: evaluate the efficacy and safety of nitazoxanide |
NCT05655780 | recruiting | not applicable | not applicable | judge prognosis: find out biomarkers to predict response and side effects during irinotecan treatment |